Transplant diagnostics Market

Globally, the rising prevalence of chronic diseases is subsequently increasing the incidence of organ failure, further surging the need for organ transplants. The Organ Donor states that over 1 million tissue transplants are performed every year. The geriatric population is highly susceptible to chronic diseases, which further increases the need for organ transplantation. As per the World Health Organization (WHO), by 2050, the world’s population aged 60 and older is expected to reach 2 billion, from 900 million in 2015. 

Chronic kidney disease (CKD) is highly prevalent and the leading cause of kidney transplantation procedures. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) states that about 661,000 Americans have Kidney failure. About 468,000 people are on dialysis, and roughly 193,000 people live with a kidney transplant.

Increased transplant diagnostic testing will result from increased organ donation, propelling industry growth. Additionally, several significant players are releasing new products on the market, which is anticipated to further fuel market revenue. For instance, in September 2021, Thermo Fisher Scientific added two new products to its range of transplant diagnostics during the American Society for Histocompatibility and Immunogenetics (ASHI) annual meeting.

There is a growing awareness regarding the importance of organ donation and transplantation, driven by educational campaigns and advocacy efforts. This heightened awareness is fostering a more supportive environment for organ donation, which in turn boosts the demand for transplant diagnostics. The Global Transplant Diagnostics Market Industry is likely to see an increase in engagement from both healthcare providers and the public, leading to improved transplant rates. This trend suggests a robust growth trajectory, with a projected CAGR of 7.31% from 2025 to 2035.

Governmental bodies and health organizations are increasingly establishing regulations and guidelines to promote safe and effective transplant practices. These regulations often include standards for transplant diagnostics, ensuring that testing methods are reliable and up to date. The Global Transplant Diagnostics Market Industry is positively influenced by this regulatory framework, as it encourages the adoption of advanced diagnostic technologies. As compliance with these guidelines becomes essential, the market is expected to expand, reflecting the growing emphasis on patient safety and quality of care.

Emerging markets are becoming increasingly important in the Global Transplant Diagnostics Market Industry. Countries with developing healthcare infrastructures are investing in transplant programs and diagnostic technologies, driven by rising healthcare expenditures. This expansion is creating new opportunities for market players to introduce their products and services. As these markets grow, they may contribute significantly to the overall market value, which is projected to reach 10.3 USD Billion by 2035. The potential for growth in these regions indicates a dynamic shift in the global landscape of transplant diagnostics.

The increasing prevalence of chronic diseases and organ failures has led to a surge in the demand for organ transplants. This trend is particularly evident in regions with aging populations, where conditions such as diabetes and cardiovascular diseases are more common. The Global Transplant Diagnostics Market Industry is responding to this demand, as evidenced by the projected market value of 4.72 USD Billion in 2024. As healthcare systems adapt to these challenges, the need for effective transplant diagnostics becomes paramount, ensuring compatibility and improving patient outcomes.

Innovations in molecular diagnostics and genetic testing are transforming the landscape of transplant diagnostics. Technologies such as next-generation sequencing and real-time PCR are enhancing the accuracy of donor-recipient matching. These advancements not only improve the success rates of transplants but also streamline the diagnostic processes. The Global Transplant Diagnostics Market Industry is likely to benefit from these technological developments, as they facilitate more personalized medicine approaches. As a result, the market is expected to grow significantly, potentially reaching 10.3 USD Billion by 2035.

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Transplant Diagnostics market is expected to grow at a significant CAGR during the study period, accounting for USD 4.95 billion in 2021. North America is a well-established market for medical devices. The presence of a highly developed healthcare system, high adoption of innovative transplant diagnostic technologies among medical professionals, the large volume of organ transplantation procedures performed in the region, and technological advancements in the field of transplant diagnostics are the major factors driving the market in North America. 

Further, the presence of many patients pool, who needs transplant treatment is helping to grow the market at a sustainable rate in this region.

Transplant Diagnostics market SHARE BY REGION 2021

Moreover, the major countries covered in the market report include the United States, Germany, Canada, France, the United Kingdom, Italy, Spain, India, Japan, Australia, China, South Korea, and Brazil.

The European Transplant Diagnostics market is the world's second-largest. Major drivers include the high adoption of advanced techniques and diagnostic tools, higher healthcare expenditure, and availability of skilled professionals. The U.K. holds the largest market share owing to factors such as highly developed healthcare infrastructure and the availability of skilled professionals. Moreover, the high adoption of personalized medicines, stem cell therapies, and soft tissue transplants are augmenting the regional market growth. 

Increase in awareness among people related to the importance of organ transplantation has been an ongoing trend in the European countries. This has resulted in increasing number of organ donations especially from living donors. Further, the UK market of Transplant Diagnostics held the largest market share, and the German market of Transplant Diagnostics was the fastest-growing market in the European region.

The Asia Pacific Transplant Diagnostics market is expected to grow at the fastest CAGR during the forecast period. This is due to the rising number of organ transplants, donors, and the government's support in developing the transplant diagnosis market in the region. The Asia Pacific comprises a large pool of patient population and developing advanced healthcare infrastructure. 

A vast rise in the prevalence of several chronic diseases and the resultant rise in transplant procedures, coupled with the availability of vast untapped growth opportunities in this region will attract many companies in the upcoming years. Moreover, China’s market of Transplant Diagnostics held the largest market share, and the Indian market of Transplant Diagnostics was the fastest-growing market in Asia-Pacific.

The global market is highly competitive with very few players competing in the international market. The quality and accuracy constraints of transplant diagnostic techniques like serology-based and PCR-based HLA typing increase the overall cost of products. As a result, players are implementing strategies, such as long-term contracts with diagnostic clinics and laboratories and discount pricing for bulk purchases.

Companies in the in the market of Transplant Diagnostics are using the

Next Generation Sequencing

(NGS) for conducting tests to match organ donors and recipients. NGS technology allows the sequencing of an entire human genome, i.e., millions of DNA molecules within a single day. In Next-generation sequencing (NSG), genes are matched between the donor and recipient and depending on the extent of match, decision to perform organ transplantation is made. Nearly all transplant diagnostic tests and devices currently use this technology to decide on organ transplantation. For example, Castle Biosciences launched Decision Dx-CMSeq Test that used NGS (Next Generation Sequencing) to identify somatic mutations in genes.

Eurofins Scientific SE is a French group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries and to governments. In June 2019, Eurofins Scientific acquired Transplant Genomics Inc to improve organ transplant outcomes with non-invasive serial monitoring guided by genomics.

Immucor Inc is a global in vitro diagnostics company specializing in the area of pre-transfusion diagnostics. The company offers a complete line of serology-based reagents and instruments used by hospitals, reference labs and donor centers to perform pre-transfusion typing and screening of blood and renders blood bank software solutions that are designed specifically to enhance the productivity of blood bank laboratories, providing transfusion test results in an efficient and productive way to the customers. 

In March 2022, Immucor, Inc., a company focused on transfusion and transplantation diagnostics, announced two additions to its transplant diagnostics portfolio, demonstrating its ongoing commitment to new advancements in the field of histocompatibility.